Please find attached.

Regulatory Product ApprovalBusiness Updates View source PDF

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.6%1-day move

₹780.90

prior close

₹780.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.3-4.5-5.5-6.9-3.6-4.0-4.1-3.1-2.9-3.6-6.2-4.0+8.8—

Up moveDown movePending

AI summary

Alembic Pharmaceuticals successfully completed a GMP inspection by Brazil's regulatory agency ANVISA at its API-III facility in Karakhadi. The inspection took place from May 11-15, 2026 and was completed without any observations - the best possible outcome. The approval clears the way for the company to export Active Pharmaceutical Ingredients to Brazil, a major pharmaceutical market. No specific orders or revenue figures were disclosed in this filing.

Likely market impact

Positive for shareholders as this regulatory approval opens access to the Brazilian pharmaceutical market for API exports. Actual financial benefit will depend on future order flow.